Knight Therapeutics Inc.
TSX:GUD.TO
5.15 (CAD) • At close November 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Knight Therapeutics Inc. |
Symbool | GUD.TO |
Munteenheid | CAD |
Prijs | 5.15 |
Beurswaarde | 520,026,400 |
Dividendpercentage | 0% |
52-weken bereik | 5.07 - 6.23 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Ms. Samira Sakhia BCom, CA, CPA, MBA |
Website | https://www.gud-knight.com |
An error occurred while fetching data.
Over Knight Therapeutics Inc.
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (CAD)
Cijfers zijn in miljoenen (CAD)